We talk with Dr Kiran Reddy about the plans for the RC-222 treatment program with the goal of developing a treatment for SCN2A gain-of-function epilepsies.
When Alex Nemiroff’s son was born, he was determined to work towards finding treatments for SCN2A, and is now CEO of RogCon with a treatment in development.